Clinical Report: CRISPR Maps T Cells Gene by Gene
Overview
A genome-scale screen utilizing CRISPR interference and single-cell RNA sequencing mapped gene regulation in CD4-positive T cells. The study identified over 2 million gene-to-gene regulatory effects.
Background
Understanding the genetic regulation of T cells is crucial for advancing immunotherapy and autoimmune disease research. This study provides insights into how individual genes influence immune responses.
Data Highlights
| Condition | Number of Genes Disrupted | Regulatory Effects Identified |
|---|---|---|
| At Rest | 11,527 | 2 million |
| 8 Hours Post-Stimulation | 7,807 | 1,556 |
| 48 Hours Post-Stimulation | 7,807 | 1,556 |
Key Findings
- 22 million CD4-positive T cells were analyzed from four healthy donors.
- 7,807 genes were found to affect the expression of at least three other genes under various conditions.
- 1,556 gene disruptions were linked to changes in cytokine production.
- Gene regulatory effects varied based on T cell activation state.
- Genes associated with autoimmune diseases were enriched in 33 of 77 regulatory clusters tested.
Clinical Implications
The findings assist in interpreting immune transcriptomic signatures and prioritizing genes identified in genome-wide association studies. The study's limitations, including the use of a small donor pool and the nature of gene repression, should be noted.
Conclusion
This research provides a comprehensive map of gene regulation in T cells. Further studies are needed to explore the clinical relevance of these findings.
Related Resources & Content
- Cell, 2023 -- CRISPR Maps T Cells Gene by Gene
- the medicine maker — CRISPR Enables In Vivo CAR T Cell Production
- the medicine maker — CRISPR and Cleaner: Gene Editing with Deep-Learning
- the medicine maker — Genetic Tailoring With CRISPR
- The ASCO Post — CRISPR-Cas9-Edited TILs: Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer
- CRISPR Enables In Vivo CAR T Cell Production
- CRISPR and Cleaner: Gene Editing with Deep-Learning
- Genetic Tailoring With CRISPR
- Cellular & Gene Therapy Guidances | FDA
- Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing | FDA
- March 18, 2026 Approval Letter - CASGEVY
- NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024 - PubMed
- ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy.
- International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML | Blood Advances | American Society of Hematology
- Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial - ScienceDirect
- Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities | Nature Reviews Clinical Oncology
- Leveraging CRISPR/Cas9 for optimized adoptive T cell therapies: From molecular engineering to clinical manufacturing - ScienceDirect
- Orthogonal CRISPR systems for targeted integration and multiplex base editing enable nonviral engineering of allogeneic CAR-T cells - PubMed
- CRISPR-screen informed engineered T cell therapies - PMC
- Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells - PMC
Based on findings from:
CRISPR Maps T Cells Gene by Gene
The Pathologist, 2026.
https://www.thepathologist.com/issues/2026/articles/september/crispr-maps-t-cells-gene-by-gene/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
